GLUE icon

Monte Rosa Therapeutics
GLUE

Overview Fund Activity

74 hedge funds and large institutions have $171M invested in Monte Rosa Therapeutics in 2024 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 7 closing their positions.

Holders
74
Holders Change
+6
Holders Change %
+8.82%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
14
Increased
33
Reduced
12
Closed
7
Calls
$374K
Puts
$89K
Net Calls
+$285K
Net Calls Change
-$304K

Top Buyers

1
SCM
1
Suvretta Capital Management
New York
$9.94M
2
Vanguard Group
2
Vanguard Group
Pennsylvania
$9.53M
3
VPC
3
Vestal Point Capital
New York
$3.33M
4
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$22.4M
5
SFM
5
Sphera Funds Management
Israel
$1.4M

Top Sellers

1
CC
1
Casdin Capital
New York
$976K
2
Fidelity Investments
2
Fidelity Investments
Massachusetts
$19.1M
3
Millennium Management
3
Millennium Management
New York
$78.3K
4
EC
4
EntryPoint Capital
New York
$0
5
AIG
5
American International Group
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
PP
76
PDT Partners
New York
– -$98.4K -13,955 Closed
Mirae Asset Global Investments
77
Mirae Asset Global Investments
South Korea
– -$80.9K -11,946 Closed
MIM
78
MetLife Investment Management
New Jersey
– -$80.5K -11,419 Closed
MLICM
79
Metropolitan Life Insurance Company (MetLife)
New York
– -$12.8K -1,820 Closed
AWM
80
Avior Wealth Management
Nebraska
– -$42 -6 Closed
1 2 3
4